首页> 美国卫生研究院文献>Aging (Albany NY) >MicroRNA-29a-3p delivery via exosomes derived from engineered human mesenchymal stem cells exerts tumour suppressive effects by inhibiting migration and vasculogenic mimicry in glioma
【2h】

MicroRNA-29a-3p delivery via exosomes derived from engineered human mesenchymal stem cells exerts tumour suppressive effects by inhibiting migration and vasculogenic mimicry in glioma

机译:通过工程化人间充质干细胞的外泌体通过外泌体递送MicroRNA-29A-3P递送通过抑制胶质瘤中的迁移和血管原性模拟物来施加肿瘤抑制作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Vasculogenic mimicry (VM), the formation of an alternative microvascular circulation independent of VEGF-driven angiogenesis, is reluctant to anti-angiogenesis therapy for glioma patients. However, treatments targeting VM are lacking due to the poor understanding of the molecular mechanism involved in VM formation. By analysing the TCGA database, microRNA-29a-3p (miR-29a-3p) was found to be highly expressed in normal brain tissue compared with glioma. An in vitro study revealed an inhibitory role for miR-29a-3p in glioma cell migration and VM formation, and further study confirmed that ROBO1 is a direct target of miR-29a-3p. Based on this, we engineered human mesenchymal stem cells (MSCs) to produce miR-29a-3p-overexpressing exosomes. Treatment with these exosomes attenuated migration and VM formation in glioma cells. Moreover, the anti-glioma role of miR-29a-3p and miR-29a-3p-overexpressing exosomes were confirmed in vivo. Overall, the present study demonstrates that MSCs can be used to produce miR-29a-3p-overexpressing exosomes, which have great potential for anti-VM therapy and may act as supplements to anti-angiogenetic therapy in the clinic.
机译:血管原性模拟(VM),形成替代微血管循环的形成与VEGF驱动的血管生成无关,对胶质瘤患者的抗血管生成治疗不情愿。然而,由于VM形成中涉及的分子机制的理解差,缺乏靶向VM的治疗。通过分析TCGA数据库,发现MicroRNA-29A-3P(MIR-29A-3P)与胶质瘤相比,在正常的脑组织中高度表达。体外研究揭示了胶质瘤细胞迁移和VM形成中miR-29a-3p的抑制作用,进一步的研究证实,Robo1是miR-29a-3p的直接靶标。基于此,我们设计了人间充质干细胞(MSCs)以产生miR-29a-3p过表达外来体。用这些外来治疗胶质瘤细胞中的迁移和VM形成。此外,在体内证实了MIR-29A-3P和MIR-29A-3P-InoSoMes的抗胶质瘤作用。总体而言,本研究表明,MSCs可用于生产miR-29a-3p-overexpressing外来体,这具有抗VM疗法的潜力很大,可作为临床抗血管生成治疗的补充。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号